AR040411A1 - Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan - Google Patents

Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan

Info

Publication number
AR040411A1
AR040411A1 AR20030101630A ARP030101630A AR040411A1 AR 040411 A1 AR040411 A1 AR 040411A1 AR 20030101630 A AR20030101630 A AR 20030101630A AR P030101630 A ARP030101630 A AR P030101630A AR 040411 A1 AR040411 A1 AR 040411A1
Authority
AR
Argentina
Prior art keywords
nhc
integer
aryl
group
cycloalkyl
Prior art date
Application number
AR20030101630A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR040411A1 publication Critical patent/AR040411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Reivindicación 1: Un método para inhibir la actividad de la polimerasa de VHC caracterizado porque comprende poner en contacto una polimerasa VHC con una cantidad eficaz de un compuesto representado por la fórmula (1) o una sal, solvato, profármaco, o metabolito del mismo; en la que r es 0, 1, 2, 3, 4 o 5; R1 es hidrógeno, o un grupo arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por grupos halógenos; =O; =S; -CN; -NO2; alcano ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; compuesto por halógeno; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3; -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -CH2CH(O)OCH3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S) H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S (O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; fenilo; cicloalcano; -O-; -OH; y CH3; R2 es un grupo isopropilo, ciclopentilo, o ciclohexilo, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS (O2) H; -NHC(SO)H; -NHC(S)H; y -SH; R3 es hidrógeno; halógeno; =S; -SH; -S-(CH2)z-heteroarilo donde z es un entero de 0 a 4; -S-(CH2)z-heterocicloalquilo donde z es un entero de 0 a 4; -S-(CH2)z-arilo donde z es un entero de 0 a 4; -(CH2)z-arilo donde z es un entero de 0 a 4; -O-arilo; -C(O)H; -C(O)-alquilo; amino; o un halógeno, sin substituir o substituido con un grupo arilo, halógenos; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; - (CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3, -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alcano, ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; fenilo; cicloalcano; -O-; -OH; y CH3; R4 es =O ó -OR5; X-W es C-CH cuando R4 es =O, y X-W es C=C cuando R4 es -OR5; o R3 y R4 junto con X y W forman un grupo cicloalquilo, heteroarilo, cicloalquilo, o heterocicloalquilo sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3, -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -CH2CH(O)OCH3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C (SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alcano, ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C (O)S(O)H; -C(O)S(O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; arilo; cicloalquilo; -OR5; haloalquilo; y alquilo; y R5 es un alquilo o H.
AR20030101630A 2002-05-10 2003-05-09 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan AR040411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37943302P 2002-05-10 2002-05-10

Publications (1)

Publication Number Publication Date
AR040411A1 true AR040411A1 (es) 2005-04-06

Family

ID=29420530

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030101630A AR040411A1 (es) 2002-05-10 2003-05-09 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan

Country Status (10)

Country Link
US (1) US7115658B2 (es)
AR (1) AR040411A1 (es)
AU (1) AU2003224371A1 (es)
DO (1) DOP2003000641A (es)
GT (1) GT200300105A (es)
PA (1) PA8573401A1 (es)
PE (1) PE20040472A1 (es)
TW (1) TW200306813A (es)
UY (1) UY27798A1 (es)
WO (1) WO2003095441A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
SI1781662T1 (sl) * 2004-08-18 2011-07-29 Pfizer Zaviralci RNA-odvisne RNA-polimeraze hepatitisa C in sestavki in zdravljenja, v katerih se uporabljajo
EP1814861A1 (en) 2004-10-29 2007-08-08 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
US7807838B2 (en) * 2005-08-24 2010-10-05 Pfizer Inc. Methods for the preparation of HCV polymerase inhibitors
DK2320905T3 (en) 2008-08-11 2017-09-18 Glaxosmithkline Llc Corp Service Company New adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
WO2011098452A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
EP2534148A1 (en) 2010-02-10 2012-12-19 GlaxoSmithKline LLC Purine derivatives and their pharmaceutical uses
US10202386B2 (en) 2014-02-20 2019-02-12 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
KR101949108B1 (ko) 2015-12-03 2019-02-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드
EA201892128A1 (ru) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
EP3440076B1 (en) 2016-04-07 2022-06-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
CA2176041A1 (en) * 1993-11-19 1995-05-26 Edmund Lee Ellsworth 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
AU689158B2 (en) 1993-11-19 1998-03-26 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
AU9198698A (en) * 1997-09-15 1999-04-05 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
AU773567B2 (en) * 1998-09-11 2004-05-27 Warner-Lambert Company HIV protease inhibitors
AU2203800A (en) * 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
ATE337309T1 (de) * 2002-04-01 2006-09-15 Pfizer Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus

Also Published As

Publication number Publication date
UY27798A1 (es) 2003-12-31
AU2003224371A1 (en) 2003-11-11
TW200306813A (en) 2003-12-01
US7115658B2 (en) 2006-10-03
US20040023958A1 (en) 2004-02-05
PE20040472A1 (es) 2004-08-12
DOP2003000641A (es) 2003-11-15
WO2003095441A1 (en) 2003-11-20
GT200300105A (es) 2004-03-17
PA8573401A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
AR040411A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
AR059201A1 (es) Compuestos citotoxicos derivados de tomaimicina
RU2015148006A (ru) Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
RU2010137808A (ru) Пестицидные композиции
CA2587528A1 (en) Method for preparing n-phenylpyrazole-1-carboxamides
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
RU2009139920A (ru) Изоксазолиновые соединения и их применение в борьбе с вредителями
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO5550501A2 (es) Derivados nucleosidos con accion sobre el virus de la hepatitis c, su procedimiento de sintesis y composiciones que los contienen
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR056191A1 (es) Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
MX2010002338A (es) Compuesto de organoazufre con fluor y composicion pesticida que lo comprende.
MX2020014087A (es) Moléculas inmunomoduladoras pequeñas novedosas.
AR059886A1 (es) Derivados de amidas como inhibidores de renina
CY1115635T1 (el) Παραγωγα 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
AR085436A1 (es) Derivados de pirrolopiridazina inhibidores de jak3, composiciones farmaceuticas que los contienen y su uso para tratar enfermedades inflamatorias y autoinmunes
DE69012486D1 (de) Überzugszusammensetzungen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal